NCT06945484

Brief Summary

This study is designed to evaluate whether a precision exercise regimen is feasible to implement within cancer populations, specifically stage II-III primary lung cancer patients receiving multimodal therapy, and delivered through telehealth.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
55mo left

Started Nov 2025

Longer than P75 for not_applicable

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress9%
Nov 2025Dec 2030

First Submitted

Initial submission to the registry

April 18, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 25, 2025

Completed
7 months until next milestone

Study Start

First participant enrolled

November 21, 2025

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2027

Expected
3.9 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2030

Last Updated

February 3, 2026

Status Verified

July 1, 2025

Enrollment Period

1.1 years

First QC Date

April 18, 2025

Last Update Submit

January 30, 2026

Conditions

NSCLC Stage IINSCLC, Stage III

Outcome Measures

Primary Outcomes (1)

  • Feasibility - Recruitment and Retention

    Feasibility of the PERCC intervention will be evaluated by our ability to recruit and retain the needed number of patients with 80% exercise intervention attendance.

    up to two months post-surgery

Secondary Outcomes (1)

  • Feasibility - Safety

    up to two months post-surgery

Study Arms (1)

Precision Exercise Regimen for Cancer Care (PERCC)

EXPERIMENTAL

Participants will engage in PERCC starting at least two weeks prior to receiving their first neoadjuvant treatment for lung cancer and continuing until two months after receiving surgical treatment.

Other: Precision Exercise Regimen for Cancer Care (PERCC)

Interventions

Precision Exercise Regimen for Cancer Care (PERCC)OTHER

PERCC has exercise modes including basic transfer and calisthenics mobility, aerobic, and resistance exercises, and will be performed in various postures (supine, sitting, standing, and walking) with variable challenges (level walking, bending, inclines, steps, and squatting). Each participant will complete one supervised, home-based exercise training session per week, delivered through telehealth, that will focus on the resistance exercise prescription. Other unsupervised exercise training sessions will focus on the aerobic exercise prescription and will be completed individually

Precision Exercise Regimen for Cancer Care (PERCC)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Ages 18 and older at time of diagnosis
  • Patient diagnosed with stage II and III non-small cell lung cancer (NSCLC)
  • Patient receives either neoadjuvant chemotherapy or immunotherapy and surgery
  • Patient able to follow direction and complete questionnaires in English or Spanish
  • Patient agrees to complete the PERCC intervention

You may not qualify if:

  • Morbidly obese (BMI \>40 kg/m2 ) or anorexic (BMI \<17.5 kg/m2 )
  • Abnormalities on screening physical exam per study physicians or physical therapist to contraindicate participation in exercise program compliance
  • Alcohol or drug abuse, significant mental or emotional problems that would interfere with compliance (assessed by NCCN Distress Thermometer)
  • Patient scheduled to receive single modality cancer treatment (unimodal therapy), scheduled to begin treatment within 2 weeks of the pre-treatment clinic visit, or for whom treatment has already started

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

University of Texas Medical Branch at Galveston

Galveston, Texas, 77555, United States

RECRUITING

Huntsman Cancer Institute

Salt Lake City, Utah, 84112, United States

RECRUITING

Related Publications (6)

  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7.

    PMID: 26742998BACKGROUND

  • Ettinger DS, Wood DE, Aggarwal C, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower M, Gettinger S, Govindan R, Gubens MA, Hennon M, Horn L, Lackner RP, Lanuti M, Leal TA, Lin J, Loo BW Jr, Martins RG, Otterson GA, Patel SP, Reckamp KL, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer KW, Yang SC, Gregory K; OCN; Hughes M. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. J Natl Compr Canc Netw. 2019 Dec;17(12):1464-1472. doi: 10.6004/jnccn.2019.0059.

    PMID: 31805526BACKGROUND

  • Tchelebi LT, Shen B, Wang M, Potters L, Herman J, Boffa D, Segel JE, Park HS, Zaorsky NG. Nonadherence to Multimodality Cancer Treatment Guidelines in the United States. Adv Radiat Oncol. 2022 Mar 8;7(5):100938. doi: 10.1016/j.adro.2022.100938. eCollection 2022 Sep-Oct.

    PMID: 35469182BACKGROUND

  • Gao SJ, Corso CD, Wang EH, Blasberg JD, Detterbeck FC, Boffa DJ, Decker RH, Kim AW. Timing of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 Feb;12(2):314-322. doi: 10.1016/j.jtho.2016.09.122. Epub 2016 Oct 5.

    PMID: 27720827BACKGROUND

  • Hanna TP, King WD, Thibodeau S, Jalink M, Paulin GA, Harvey-Jones E, O'Sullivan DE, Booth CM, Sullivan R, Aggarwal A. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ. 2020 Nov 4;371:m4087. doi: 10.1136/bmj.m4087.

    PMID: 33148535BACKGROUND

  • Yalman D. Invited Editorial on "the timing of surgery after neoadjuvant chemoradiation in locally advanced non-small cell lung cancer". J Thorac Dis. 2017 Mar;9(3):E299-E300. doi: 10.21037/jtd.2017.02.98. No abstract available.

    PMID: 28449527BACKGROUND

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Carcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Cornelia Ulrich, MS, PhD

    Huntsman Cancer Institute/ University of Utah

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Thomas Varghese, MD, MS, MBA, FACS

CONTACT

801-581-5311thomas.varghese@hsc.utah.edu

Cornelia Ulrich, MS, PhD

CONTACT

801-213-5716neli.ulrich@hci.utah.edu

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 18, 2025

First Posted

April 25, 2025

Study Start

November 21, 2025

Primary Completion (Estimated)

January 1, 2027

Study Completion (Estimated)

December 1, 2030

Last Updated

February 3, 2026

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will not share

Locations

US(2)